US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.89 ▼-1.02% TSLA $378.69 ▲+2.18% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% SNDK $1,704.16 ▼-0.92% AAPL $332.89 ▼-0.24%
FinancialContent

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock (NQ:XOMAP)

24.98 UNCHANGED
Last Price Updated: 3:06 PM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

< Previous 1 2 3 Next >
News headline image
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio 
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
From XOMA Corporation
Via GlobeNewswire
News headline image
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024 
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Announces Stock Repurchase Program of up to $50 Million
Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive total shareholder return 
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024 
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Added to the Russell 2000® and Russell 3000® Indexes
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
New Drug Application for arimoclomol in NPC to be filed as early as the third quarter of 2023¹ 
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy
From XOMA Corporation
Via GlobeNewswire
< Previous 1 2 3 Next >